Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Justdosomeddon Jan 11, 2023 1:26pm
164 Views
Post# 35216249

Dr. Peter Dicpinigaitis Appointed to the Advisory Board

Dr. Peter Dicpinigaitis Appointed to the Advisory Board
It’s important for a company to have a strong advisory board to help guide them toward the right path. $AGN.C just appointed Dr. Peter Dicpinigaitis to the board, and he certainly has the qualifications to back him up.
 
- He is a faculty member of the Division of Critical Care Medicine at Montefiore Medical Center
- Is the founder and director of the Montefiore Cough Center, a specialty centers committed to the evaluation and management of patients with chronic coughs.
- Has authored/co-authored numerous journals and guidelines over his 25 years of experience in the space.
 
Due to his expertise around cough, without a doubt, he’ll be a key player for the company’s success moving into 2023 as they continue to undergo trials for their repurposed drug program.
 
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-appoints-dr-peter-120000953.html
 
Beyond this, $AGN.C has been working hard in developing their flagship treatments with the recently announced 180-patient, 90-day Phase 2b study of Ifenprodil for chronic cough in Q3 (https://themarketherald.ca/algernon-pharmaceuticals-announces-plans-for-a-180-patient-phase-2b-chronic-cough-study-of-ifenprodil-2023-01-09/). And with significant IP/market potential backing $AGN.C from their use of DMT on stroke victims to Ifenprodil on chronic cough (which has received an orphan designation from the FDA), the current $5.3M valuation provides significant upside potential, especially when considering the promising results from the previous studies. Definitely keep an eye out as they continue their trials and get closer to full approval.
<< Previous
Bullboard Posts
Next >>